Blog – Adragos Pharma https://adragos-pharma.com Your Global CDMO Mon, 20 Jul 2026 09:08:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.3 https://adragos-pharma.com/wp-content/uploads/2024/04/cropped-Adragos-Pharma-Symbol-2024-32x32.png Blog – Adragos Pharma https://adragos-pharma.com 32 32 Root Cause Analysis in Stability Testing: Turning OOS and OOT Signals into GMP Decisions https://adragos-pharma.com/root-cause-analysis-in-stability-testing-turning-oos-and-oot-signals-into-gmp-decisions/ https://adragos-pharma.com/root-cause-analysis-in-stability-testing-turning-oos-and-oot-signals-into-gmp-decisions/#respond Mon, 20 Jul 2026 09:08:38 +0000 https://adragos-pharma.com/?p=26417 In pharmaceutical development and manufacturing, stability testing is not simply a regulatory requirement. It is one of the most important ways we protect patients, preserve product quality, and maintain confidence in the product throughout its lifecycle.

For sponsors outsourcing development and manufacturing activities, stability data is also a critical decision-making tool. It informs shelf life, packaging choices, formulation understanding, regulatory submissions, and long-term product control. When a stability signal appears, whether it is an Out-of-Specification (OOS) result, an Out-of-Trend (OOT) result, an atypical chromatogram, or a change in degradation behaviour, the question is not only “what happened?” The more important question is “why did it happen, and what evidence supports that conclusion?”

That is where root cause analysis becomes essential.

From the analytical stability laboratory perspective, RCA is not an administrative exercise. It is a structured, evidence-led process that connects analytical data, product knowledge, laboratory controls, manufacturing history, packaging information, and quality oversight. The goal is not to reach the fastest answer. It is to reach the right answer, quickly enough to support GMP decisions without compromising scientific rigour.

Why stability RCA is different

A release test or in-process control result often reflects a specific batch at a specific point in time. Stability testing is broader. It looks at how a product behaves over time under defined storage conditions.

That changes the nature of the investigation. A stability signal may be linked to analytical performance, but it may also reflect product degradation, humidity sensitivity, light exposure, temperature impact, packaging interaction, formulation characteristics, transport history, or manufacturing variability. The laboratory therefore cannot assess the result in isolation. It must consider the product’s expected behaviour over time.

This is particularly important during the registration phase, where stability studies are often based on a limited number of registration batches. In that context, the available data set may be smaller than in routine commercial manufacturing. For a development-focused site, meaningful interpretation often requires stability results to be assessed alongside development-phase data, formulation knowledge, packaging information, and manufacturing history.

OOS is clear. OOT is often more challenging

An OOS result is outside an approved specification. It is therefore a clear trigger for formal investigation.

An OOT result can be more complex. The result may still be within specification, but it does not align with the expected stability profile or product behaviour. This could include an assay shift, a change in impurity profile, an unexpected degradation pattern, atypical dissolution behaviour, or a physical chemistry result that differs from historical expectations.

For stability studies, OOT signals matter because they can provide an early warning before a product reaches an OOS condition. The analytical result may still be technically acceptable against the specification, but the trend may suggest that something is changing.

In a development or registration context, classical statistical trending may not always be possible because the number of batches is limited. The SME input highlighted that, in such cases, the stability team may use the concept of significant change, for example a notable assay difference from the initial value, together with development knowledge and stability history. This makes scientific judgement, data integrity, and documented rationale especially important.

The first step: structured preliminary investigation

When a signal appears, the first risk is to jump too quickly to a conclusion. A robust stability RCA begins with a structured preliminary investigation.

The laboratory reviews the analytical data, chromatograms, calculations, system suitability criteria, instrument status, sample handling, method execution, and documentation. The purpose is to determine whether the signal can be explained by an obvious laboratory or analytical factor before broader product-related hypotheses are explored.

This phase typically considers the routine laboratory investigation categories: man, machine, material, method, environment, and measurement. In practical terms, that means asking whether the analyst followed the method correctly, whether the HPLC column or instrument was performing as expected, whether standards and reagents were suitable, whether the sample was handled correctly, whether the calculations and data transfers were accurate, and whether the chromatographic profile supports the reported result.

Good Documentation Practices and ALCOA+ data integrity principles are central at this stage. The quality of the investigation depends on the quality of the evidence. Raw data, timing, sample records, chromatograms, integration parameters, analyst observations, and review comments all help reconstruct what happened.

From checklist to hypotheses

If the preliminary investigation identifies a clear cause, such as a documented analytical error, this is recorded and corrected according to procedure. The next steps may include justified repeat analysis, depending on the approved investigation process.

If no obvious cause is found, the investigation becomes hypothesis-driven. This is where technical judgement matters.

The team asks: what mechanisms could realistically explain the observed result?

Potential hypotheses may include method performance, sample preparation, instrument behaviour, column performance, solution stability, mobile phase preparation, analyst technique, environmental exposure, storage conditions, product degradation pathways, packaging interaction, or formulation sensitivity.

Each hypothesis must be testable. It must be supported or ruled out through objective evidence, not preference, pressure, or assumption. This is the point where a strong laboratory culture matters. Effective RCA requires curiosity, discipline, and healthy scepticism. It also requires the courage to slow down just enough to avoid a weak conclusion.

Method performance: proving or ruling out the analytical cause

The analytical method itself is often one of the first areas assessed. System suitability is a critical first line of evidence because it provides immediate information on method and instrument performance during the analysis.

Validation and ongoing method controls also support RCA. Robustness studies help determine whether small variations in analytical conditions could influence results. Precision and intermediate precision data help assess variability between analysts, instruments, and testing days. Column history, instrument qualification, historical method performance, integration parameters, carry-over checks, and chromatographic review can all help determine whether the signal is truly product-related or linked to the analytical process.

This is where laboratory experience becomes valuable. A validated method can still require careful interpretation in the context of a specific product, degradation pathway, or stability condition. The investigation must assess not only whether the method passed its criteria, but whether the method behaviour explains the result observed.

RCA is cross-functional work

A stability RCA cannot be owned by the laboratory alone.

The analytical team reviews the test execution, data, chromatograms, method controls, and technical findings. QA ensures that the investigation follows internal procedures, GMP expectations, and appropriate documentation standards. Stability management provides study context. Development contributes formulation knowledge, degradation pathway understanding, and product history. The CMO may need to provide manufacturing process data, packaging operation details, deviation history, or batch records.

For sponsors outsourcing development and manufacturing, this is one of the most important practical lessons. The strength of an RCA often depends on the accessibility and completeness of data across organisations. Missing manufacturing records, incomplete packaging information, unclear change history, or delayed communication can slow the investigation and weaken the conclusion.

A good CDMO or CDO partner does not simply “run the test.” It helps connect the data chain across development, analytical testing, stability, quality, manufacturing, and supply.

CAPA must prevent recurrence, not just close the investigation

Once the root cause is identified, the Corrective and Preventive Action must do two things. It must address the immediate issue, and it must reduce the risk of recurrence.

Depending on the root cause, CAPA may include method updates, SOP improvements, additional controls, enhanced monitoring, analyst retraining, instrument maintenance, equipment replacement, or changes to sample handling practices. When method improvement is involved, effectiveness may be demonstrated directly through improved analytical results. When the CAPA relates to human performance, instrument-related incidents, or recurring laboratory errors, effectiveness often needs to be evaluated over time through trending.

The SME input highlighted the value of annual trending of laboratory investigation reports, analytical errors, and instrument-related incidents. This allows the site to assess whether implemented actions are reducing recurrence and whether further actions are needed.

What sponsors should take away

For pharma sponsors outsourcing development and manufacturing, stability RCA is faster and more robust when the right information is available from the beginning.

That means analytical development data, manufacturing history, packaging information, formulation knowledge, stability protocols, storage conditions, deviation history, and change control records should be accessible and well organised. Sponsors should also expect their CDMO partner to follow a structured process: preliminary investigation, data review, hypothesis generation, evidence testing, documented conclusion, CAPA, and effectiveness monitoring.

The strongest RCA is not driven by assumptions. It is driven by evidence.

In stability testing, this discipline matters because the consequences extend beyond a single result. Stability signals can affect shelf life, regulatory commitments, batch disposition, market supply, and patient confidence. GMP is, ultimately, a contract with patients. Root cause analysis is one of the ways we honour that contract: by following the data, asking the right questions, and acting with scientific and operational discipline.

]]>
https://adragos-pharma.com/root-cause-analysis-in-stability-testing-turning-oos-and-oot-signals-into-gmp-decisions/feed/ 0
How to Evaluate a Small Molecule CDMO: Essential 2026 Guide https://adragos-pharma.com/how-to-evaluate-a-small-molecule-cdmo/ https://adragos-pharma.com/how-to-evaluate-a-small-molecule-cdmo/#respond Fri, 17 Jul 2026 09:16:18 +0000 https://adragos-pharma.com/?p=26380 Knowing how to evaluate a small molecule CDMO is what stands between a smooth development programme and an expensive misstep. A small molecule Contract Development and Manufacturing Organization (CDMO) takes an active ingredient and turns it into a formulated, tested, regulatory-ready product, so the evaluation has to look well beyond price. This 2026 framework sets out the criteria that matter most: regulatory track record, development depth across dosage forms, fit for value-added medicines and niche generics, and readiness to supply global markets.

What does it mean to evaluate a small molecule CDMO?

To evaluate a small molecule CDMO is to judge whether a partner can carry your molecule from early development through to an approved, marketable product. It is a broader question than manufacturing alone, because the value sits in the science and the regulatory work as much as in the production line. A sound evaluation weighs four things:

  • The regulatory track record, meaning approvals actually achieved.
  • The depth of development capability across dosage forms.
  • The fit for your product type, whether value-added medicine or niche generic.
  • The readiness to supply the markets you are targeting.

Regulatory track record: the strongest signal

Nothing predicts future success like a proven regulatory record. Ask how many dossiers the CDMO has compiled and submitted, in which formats, and how many products have actually been approved. A partner that works in electronic Common Technical Document (eCTD) format and has interacted directly with regulators is far more likely to steer your dossier to approval. Our Athens site, for example, has made more than one hundred and fifty eCTD submissions, achieved product approvals in more than twenty countries, and held more than twenty scientific advice meetings with European authorities, including the European Medicines Agency, with two Qualified Persons for release.

Development depth across dosage forms

A capable small molecule CDMO can formulate more than one type of product. Look for genuine depth across oral, topical and parenteral dosage forms, supported by in-house formulation development, analytical development and clinical science. Our Athens site works as a Center of Excellence for galenic development, covering tablets, capsules, effervescent and orodispersible tablets, creams, ointments, gels, ophthalmic and nasal products, and it has run more than one hundred bioequivalence studies with over two thousand eight hundred volunteers. That breadth means a molecule can be matched to the right formulation rather than forced into the only one on offer.

Fit for value-added medicines and niche generics

Small molecule programmes often live in two spaces: value-added medicines, which improve a known molecule for patients, professionals or payers, and niche generics, which face little competition beyond the originator. Both reward a partner that understands the market as well as the chemistry. If your strategy centres on value-added medicines or niche generics, check that the CDMO has a real record in that space rather than only in standard generics. Our Athens site specialises in exactly this, developing value-added medicines, new chemical entities and niche generics for global markets.

Global market readiness

An approval in one market is only the start. Assess whether the CDMO can support supply and registration across the regions you are targeting, and whether it can manage the wider supply chain around your product. Our Athens site keeps more than seventy stock keeping units in supply, works with more than twenty-five European contract manufacturers, and supports out-licensing, so a product can move from development into commercial supply and into new markets without losing momentum. If your molecule is highly potent, containment becomes a separate dimension of the evaluation, which we cover in our guide on choosing a small molecule HPAPI CDMO.

A small molecule CDMO evaluation checklist

Use this short checklist to structure your assessment:

  • How many dossiers has the CDMO submitted, and in how many countries have products been approved?
  • Does it work in electronic Common Technical Document format and interact directly with regulators?
  • Which dosage forms can it formulate in-house?
  • Does it have a real record in value-added medicines or niche generics?
  • Can it support the markets and the supply chain you are targeting?
  • Does it hold EU-GMP and support United States Food and Drug Administration requirements?

How Adragos measures up as a small molecule CDMO

Our Athens site is built around small molecule development, with more than twenty-five years of experience and over seventy professionals engaged in pharmaceutical research and development. We keep development in-house from inception to commercialisation, across:

  • Formulation development, analytical development and clinical science under one roof.
  • A regulatory record of more than one hundred and fifty eCTD submissions and approvals in more than twenty countries.
  • A focus on value-added medicines, new chemical entities and niche generics.
  • EU-GMP certification and readiness for United States Food and Drug Administration requirements.

To discuss a specific molecule, contact our development team.

Frequently asked questions

What is a small molecule CDMO?

A small molecule CDMO is a Contract Development and Manufacturing Organization that develops and manufactures conventional chemical drug products, taking an active ingredient through formulation, analytical work and regulatory submission to an approved product.

What is the difference between a value-added medicine and a generic?

A generic reproduces an existing product, while a value-added medicine improves a known molecule, for example through a new formulation or route of administration, to deliver a relevant benefit for patients, professionals or payers.

Why does regulatory track record matter when evaluating a CDMO?

Approvals achieved are the clearest evidence that a CDMO can navigate the regulatory path. A partner with many submissions and approvals across markets is more likely to steer your dossier to a successful outcome.

Can a small molecule CDMO handle highly potent APIs?

Some can, but high-potency handling requires specific containment. This is a separate part of the evaluation, covered in our guide on choosing a small molecule HPAPI CDMO.

]]>
https://adragos-pharma.com/how-to-evaluate-a-small-molecule-cdmo/feed/ 0
What Is GMP Compliance for CDMO Manufacturing https://adragos-pharma.com/gmp-compliance-for-cdmo-manufacturing/ https://adragos-pharma.com/gmp-compliance-for-cdmo-manufacturing/#respond Fri, 17 Jul 2026 08:30:04 +0000 https://adragos-pharma.com/?p=26365 GMP compliance for CDMO manufacturing is the set of Good Manufacturing Practice standards that a Contract Development and Manufacturing Organization (CDMO) must meet to produce medicines safely, consistently and in a way that regulators will accept. When a pharmaceutical or biotech company selects a manufacturing partner, GMP compliance is the baseline that separates a credible CDMO from a risky one. This guide explains the certifications, the aseptic standards and the quality criteria to assess, across both semi-solid and injectable production.

What is GMP compliance for CDMO manufacturing?

GMP compliance for CDMO manufacturing means that a site operates under Good Manufacturing Practice, the framework of rules that governs how medicines are made, tested, documented and released. In practice it covers the facilities, the equipment, the personnel, the procedures, the quality control and the record keeping. A compliant CDMO can demonstrate all of this through current certifications and a clean regulatory inspection record. It is the foundation that every other capability rests on, because a process is only as good as the quality system that runs it.

The core GMP certifications to look for

Certifications tell you which markets a CDMO can legally supply, so they are the first filter when comparing CDMO services. Look for the following:

  • European Union Good Manufacturing Practice (EU-GMP), the baseline for supplying medicines in Europe.
  • United States Food and Drug Administration approval, required to supply the United States.
  • Swissmedic certification for sites in Switzerland.
  • National approvals such as Japan PMDA, Brazil ANVISA or China NMPA, where you supply those markets.

You can review the European framework on the European Medicines Agency good manufacturing practice pages. A CDMO that already holds the certifications for your target markets saves you time and reduces regulatory risk.

Aseptic standards for injectable production

Injectable production carries the highest contamination risk, so it is held to additional aseptic standards on top of general GMP. Confirm that the site fills within a Restricted Access Barrier System (RABS) or isolator, with a Class A critical zone surrounded by a Class B environment, in line with the revised European Union Good Manufacturing Practice Annex 1 on sterile products. Ask to see a current, fully compliant Aseptic Process Simulation (APS), which is the media fill that proves the line can maintain sterility. The United States Food and Drug Administration guidance on sterile drug products produced by aseptic processing sets out the expectations in detail. Our sterile sites are built to these standards, with aseptic fill-finish and full Aseptic Process Simulation at our Jura site, and Class A in Class B RABS filling at our Maisons-Alfort site.

Quality criteria for semi-solid and non-sterile production

GMP compliance is not only about sterile products. For semi-solid dosage forms such as creams, gels and ointments, and for non-sterile liquids, look for a facility with robust batch control, controlled drug handling where needed, and certification for the product types you make. Our Leipzig site in Germany, for example, holds EU-GMP certification for both human and veterinary products, which is useful for companies with a mixed portfolio. The principle is the same across every dosage form: consistent quality, fully documented, batch after batch.

How GMP compliance supports technology transfer

Technology transfer depends on GMP compliance at both ends. When a process moves from development into manufacturing, or from one site to another, the sending and receiving sites must operate to the same standards for the transfer to hold. This is where an integrated network helps: when sites share one quality system, technology transfer is faster and carries less risk, because the documentation, the controls and the expectations already align.

How to verify a CDMO’s GMP compliance

Do not take GMP compliance on trust. Ask for the evidence:

  • Current GMP certificates for the relevant markets.
  • The regulatory inspection history and record of critical findings.
  • Audit rights and a clear quality agreement.
  • The site approach to deviations and Corrective and Preventive Actions (CAPA).

For a full walk-through of what to check on site, see our guide on how to audit a sterile injectable CDMO.

How Adragos maintains GMP compliance across its network

We hold the certifications required to supply medicines across Europe, the United States, Japan and beyond, at every site in our network:

  • Leipzig, Germany: EU-GMP certification for human and veterinary semi-solid and non-sterile liquid products.
  • Jura, Switzerland: EU-GMP, United States Food and Drug Administration approval and Swissmedic, with full Aseptic Process Simulation for sterile fill-finish.
  • Maisons-Alfort, France: certified by twelve international health authorities, with an inspection record in which every action has been closed with zero critical findings.
  • Halden, Norway: EU-GMP and United States Food and Drug Administration approval alongside authorities in Brazil, Japan and China, supplying more than seventy-five countries.
  • Livron, France: EU-GMP with additional French and Korean approvals for sterile liquids and suppositories.

To discuss the certifications relevant to your product, contact our team.

Frequently asked questions

What does GMP stand for?

GMP stands for Good Manufacturing Practice, the framework of standards that governs how medicines are made, tested, documented and released to ensure they are safe and consistent.

What certifications should a CDMO have?

At a minimum, look for European Union Good Manufacturing Practice and, where you supply the United States, United States Food and Drug Administration approval. Swiss sites should hold Swissmedic, and national approvals such as Japan PMDA or Brazil ANVISA matter for those markets.

Is GMP the same for semi-solid and injectable production?

The core GMP principles are the same, but injectable production adds aseptic standards, including Restricted Access Barrier System or isolator filling, Annex 1 requirements and Aseptic Process Simulation, because sterility must be assured.

How can I confirm a CDMO is GMP compliant?

Ask for current GMP certificates, the regulatory inspection history, audit rights and a quality agreement. A compliant partner will share these openly and support an on-site audit.

]]>
https://adragos-pharma.com/gmp-compliance-for-cdmo-manufacturing/feed/ 0
CDMO Tech Transfer: Semi-Solids & Injectables https://adragos-pharma.com/cdmo-tech-transfer-semi-solids-injectables/ https://adragos-pharma.com/cdmo-tech-transfer-semi-solids-injectables/#respond Tue, 14 Jul 2026 11:32:38 +0000 https://adragos-pharma.com/?p=26339



CDMO Tech Transfer: Semi-Solids & Injectables | Adragos


Technology transfer to a contract development and manufacturing organisation (CDMO) for semi-solid or sterile injectable pharmaceutical products is a structured, multi-stage programme through which a product’s formulation, manufacturing process and quality control methods are formally conveyed from a sending organisation to a receiving manufacturing site. When executed correctly, it enables the receiving site to reproduce a product that consistently meets its approved quality specifications, at the required scale and under full Good Manufacturing Practice (GMP) compliance. Adragos Pharma provides CDMO services for semi-solid and injectable programmes across a network of GMP-certified facilities in Germany, Switzerland and France, supporting transfers from clinical development through to large-scale commercial supply.

What Technology Transfer Means in a CDMO Context

In pharmaceutical contract manufacturing, technology transfer is not a simple handover of documents. It is a controlled, step-wise programme that transfers product and process knowledge from a sending organisation to a receiving site, while demonstrating that the receiving site can reproduce the product’s critical quality attributes within validated parameters.

The programme is governed by internationally recognised frameworks. The International Council for Harmonisation (ICH) Q10 guideline on Pharmaceutical Quality Systems provides the overarching framework for knowledge management and transfer. ICH Q8 (Pharmaceutical Development) and ICH Q11 (Development and Manufacture of Drug Substances) inform the depth of process understanding expected of the sending party. In Europe, the EU GMP guidelines (EudraLex Volume 4) establish specific obligations for both the sending and receiving sites across three domains:

  • Process knowledge transfer: Manufacturing methods, batch records, critical process parameters and in-process control ranges
  • Analytical method transfer: Quality control methods, reference standards, acceptance specifications and method validation data
  • Quality and regulatory documentation: Dossier summaries, stability data, validation reports and post-approval change strategies

A technology transfer programme that is poorly scoped, under-resourced or lacking senior scientific oversight introduces risk at every subsequent stage of development and supply. Selecting the correct CDMO partner — and understanding the full scope of what transfer requires — is therefore a strategic decision, not a procedural one.

How to Qualify a CDMO Partner for Technology Transfer

Before any transfer activity begins, the pharmaceutical company must conduct a thorough technical and quality qualification of its prospective CDMO. A mismatch in manufacturing scale, dosage form expertise or regulatory standing creates programme risk that is difficult to remediate once a transfer is underway.

GMP Certification and Regulatory Standing

The receiving site must hold a valid GMP manufacturing authorisation issued by the relevant competent authority for each market in which the product will be commercialised. For European markets, EU GMP certification is mandatory. For products with global distribution requirements, certifications from the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) significantly simplify regulatory filings across those markets.

Dosage-Form-Specific Infrastructure

Semi-solid and injectable manufacturing require fundamentally different facility designs, equipment and environmental controls. No amount of general pharmaceutical experience compensates for the absence of validated, dosage-form-specific manufacturing capability. A CDMO must be able to demonstrate active, validated operation in the specific dosage form being transferred, not theoretical capacity.

Quality Management System Maturity

A CDMO’s quality management system must demonstrate robust deviation management, formal change control procedures, structured risk management and a consistent record of regulatory inspection readiness. Inspection outcomes and client audit frequency are reliable indicators of operational quality culture. A site receiving twelve client audits per year, for example, demonstrates a level of transparency and confidence in its quality systems that is difficult to replicate in a site with limited audit history.

Scientific and Technical Team Competence

The expertise of the receiving site’s scientists and manufacturing specialists directly determines the success of the transfer. Experience in formulation development, process characterisation and process validation for the relevant dosage form, accumulated across a significant number of active programmes, is essential and should be verified during qualification.

Good Manufacturing Practice Obligations Governing Technology Transfer

Under EU GMP, technology transfer activities are subject to Chapter 6 (Quality Control), Chapter 7 (Outsourced Activities) and relevant EMA guidance on technology transfer. Annex 15 of the EU GMP guidelines (Qualification and Validation) governs the validation activities that the receiving site must complete prior to commercial manufacture.

Key GMP obligations during a technology transfer include:

  • A formal Technology Transfer Protocol defining scope, responsibilities, acceptance criteria, escalation routes and timelines
  • A Transfer Report documenting all experimental outcomes, deviations, investigations and sign-off approvals
  • Analytical method transfer studies demonstrating that the receiving laboratory can reproduce results from the sending site within pre-established acceptance criteria
  • Process validation at the receiving site, structured around the stages defined in Annex 15: Installation Qualification, Operational Qualification, Performance Qualification and, following commercial launch, Continued Process Verification
  • Qualified Person oversight and batch release at every GMP manufacturing stage, including for clinical investigational medicinal products

Regulatory Note: Qualified Person Batch Release

Under EU GMP, every batch of finished medicinal product manufactured within the European Union must be certified by a Qualified Person before it is released for sale or supply. This obligation applies equally to clinical investigational medicinal products. When selecting a CDMO partner, confirming that Qualified Person certification covers all planned manufacturing stages — from clinical trial material production through to commercial batch release — is a fundamental due diligence requirement. Failure to establish this at the outset creates a compliance gap that can delay or prevent product release.

Change control procedures must be invoked whenever a process parameter, material specification or in-process test deviates from what was defined in the Technology Transfer Protocol. Regulatory notification requirements depend on the nature and scope of the change relative to the approved dossier.

The Technology Transfer Process: A Step-by-Step Overview

A structured technology transfer for semi-solid or injectable manufacturing proceeds through defined stages, each of which must be completed and formally reviewed before the next begins.

Stage One: Feasibility Assessment and Gap Analysis

The programme begins with a technical feasibility review. The CDMO assesses whether its facility, equipment portfolio and process knowledge are compatible with the product being transferred. A gap analysis identifies all differences between the originating and receiving sites that must be resolved before experimental work begins.

For semi-solid products, gap analysis addresses mixing and homogenisation equipment compatibility, available batch size ranges, filling equipment formats for the specific primary container and environmental controls for temperature-sensitive formulations. For sterile injectables, gap analysis covers aseptic process design, container closure systems, lyophilisation cycle parameters, filling line compatibility and the regulatory filing requirements across each target market.

Stage Two: Technical Package Review and Documentation Transfer

Once feasibility is established, the sending party provides a comprehensive technical package. This includes master batch records, process descriptions, analytical methods, raw material specifications, stability data, regulatory dossier summaries and validation reports. The receiving site’s technical and quality teams review this documentation in its entirety to identify any gaps, ambiguities or updates required before laboratory or manufacturing work commences.

Stage Three: Analytical Method Transfer

Quality control methods must be formally transferred and verified at the receiving site’s laboratory before any batch manufacture begins. Transfer studies involve comparative testing or co-validation experiments designed to demonstrate equivalent analytical performance between the sending and receiving laboratories within defined acceptance criteria.

For injectable products, this includes sterility testing, endotoxin testing, bioburden determination and High Performance Liquid Chromatography (HPLC) method validation. For semi-solid products, method transfer typically encompasses viscosity determination, pH testing, assay methodology and, where applicable, dissolution or release testing.

Stage Four: Pilot Batch Manufacture

Pilot batches produced at a representative scale allow the receiving site to verify process reproducibility before full-scale manufacture. These batches confirm that equipment parameters, processing conditions and in-process control procedures consistently produce a product meeting the quality specifications established at the originating site. All deviations are formally documented, investigated and resolved through the change management procedures agreed upon at the outset of the programme.

Stage Five: Process Validation and Scale-Up

Process validation at the receiving site must demonstrate that the manufacturing process, when operated within its defined parameter space, consistently produces a product of the required quality. For scale-up programmes, critical process parameters must be evaluated at the intended commercial batch scale to confirm that the product’s critical quality attributes are maintained as equipment geometry, fluid volumes and heat transfer profiles change.

Stability studies initiated during this stage support the regulatory variation or supplement submission required to authorise manufacture at the new site. The scope and filing pathway for that variation will depend on the product’s existing approval status and the regulatory agencies with jurisdiction.

Stage Six: Commercial Supply and Continued Process Verification

Following process validation approval and the resolution of any regulatory filing requirements, the site transitions to routine commercial manufacturing. Continued Process Verification activities monitor process performance data on an ongoing basis to detect trends or signals of process drift, supporting the validated state and the long-term control strategy.

Technical Considerations for Semi-Solid Technology Transfer

Semi-solid pharmaceutical products including creams, gels, ointments and healing pastes present specific technical challenges during technology transfer. Their rheological behaviour, physical stability and in-process characteristics are sensitive to manufacturing variables that do not scale linearly between sites or between batch sizes.

Product Type Key Technical Challenges at Transfer Critical Process Parameters
Creams and emulsions Droplet size distribution, phase separation risk, emulsification efficiency at scale Temperature during emulsification, mixing speed, homogeniser intensity, cooling rate
Gels Polymer hydration uniformity, air entrapment, viscosity consistency across batch volume Hydration time and temperature, mixing sequence, pH adjustment point
Ointments Active Pharmaceutical Ingredient (API) dispersion uniformity, waxy base behaviour at scale Temperature of API incorporation, mixing time, batch homogeneity sampling
Healing pastes High-viscosity handling, equipment shear tolerance, filling accuracy at increased viscosity Mixing speed, temperature profile, filling pressure and speed

Scale-Dependent Mixing and Homogenisation Behaviour

The fluid dynamics of a semi-solid preparation change materially with increasing batch scale. Shear rates, mixing times and heat transfer rates that produce a given microstructure at pilot scale may not replicate at a larger vessel without process re-characterisation. The receiving site must have the analytical and process development capability to determine appropriate parameter ranges at the intended commercial scale, rather than simply transcribing those from the originating site.

Container and Closure System Compatibility

Semi-solid products are filled into aluminium tubes, plastic tubes and laminate tubes across a range of fill weights. The receiving site must operate validated filling equipment that is compatible with the specific container format, fill weight range and sealing mechanism required. Line clearance procedures and in-process fill weight controls must be aligned with the product’s specifications from the outset.

Environmental and Temperature Controls

Many semi-solid formulations require controlled temperature conditions during bulk manufacture, transfer and filling. The manufacturing facility must demonstrate validated environmental control systems that maintain the required conditions throughout each stage of the process.

Physicochemical Stability and Acceptance Testing

Rheological properties including spreadability, consistency, appearance and phase homogeneity are key quality attributes for semi-solid products and must be incorporated into the stability programme initiated at the receiving site. Stability chambers must be qualified to support the ICH climate zones relevant to the target markets.

Technical Considerations for Sterile Injectable Technology Transfer

Sterile injectable manufacturing operates within the most demanding regulatory and technical environment in pharmaceutical production. Technology transfer for liquid vials, lyophilised vials, prefilled syringes and ampoules requires precise process characterisation and rigorous contamination control at every stage.

Injectable Format Key Technical Challenges at Transfer Critical Considerations
Liquid vials Sterility assurance, container closure integrity, particulate control Aseptic process design, fill volume accuracy, stopper compatibility
Lyophilised vials Cycle transfer between freeze-dryers of differing geometry and capacity Collapse temperature data, residual moisture targets, shelf temperature uniformity
Prefilled syringes Container system compatibility, plunger functionality, breakloose and glide force Syringe barrel material, silicone level, tip cap and needle integration
Ampoules Sealing integrity, particulate generation during sealing, terminal sterilisation compatibility Fill volume control, sealing conditions, pinhole detection validation

Aseptic Process Design and Simulation

For products requiring aseptic manufacture, the receiving site must operate within a validated aseptic processing environment and demonstrate its sterility assurance through formal Aseptic Process Simulation, commonly referred to as a media fill study. The design of the filling environment, including the use of Restricted Access Barrier Systems (RABS) or isolator technology, must be evaluated for compatibility with the specific product’s viscosity, filling volume and container format.

Lyophilisation Cycle Development and Transfer

For freeze-dried products, the lyophilisation cycle is a critical process parameter set that must be fully characterised at the receiving site. Differences in freeze-dryer shelf area, condenser capacity, vacuum system performance and control system architecture between the originating and receiving equipment may require cycle re-development and formal comparability studies. Residual moisture targets and collapse temperature data established during development must be reproduced under the receiving site’s conditions.

Container Closure Integrity Evaluation

The combination of primary container and closure must be evaluated for compatibility with the product formulation and validated for integrity across the intended shelf life. For prefilled syringes, this includes assessment of the syringe barrel material, plunger configuration, tip cap and, where relevant, the attached needle system. Container closure integrity testing methodology and acceptance criteria must be established and validated at the receiving site.

Regulatory Variation and Dossier Submissions

A change of manufacturing site for a sterile injectable product requires a regulatory variation or supplement submission to each authority with jurisdiction over the approved product. The classification of that variation, and therefore the data package required, depends on the product’s regulatory history, the nature of the change and the market concerned. CDMOs with active regulatory affairs experience across the relevant geographies provide meaningful support in scoping, preparing and filing these submissions.

Controlled Substance Handling

Where the injectable product contains a controlled substance, the receiving site must hold the appropriate national narcotic handling licence and demonstrate validated procedures for secure storage, weighing, dispensing and reconciliation throughout the manufacturing process. Regulatory authorities require full accountability records across all controlled substance operations.

Adragos Pharma: CDMO Manufacturing Network at a Glance

Adragos Pharma operates GMP-certified manufacturing sites across Germany, Switzerland and France, with additional capabilities in Japan. Each site provides validated, dosage-form-specific capability to support technology transfer programmes targeting multiple markets — from clinical trial material supply through to large-scale commercial production.

Site Location Primary Dosage Forms Key Certifications
Leipzig Germany Semi-solids, non-sterile liquids EU GMP (human & animal)
Jura Switzerland Sterile liquid and lyophilised vials EMA, FDA, Swissmedic
Maisons-Alfort France Prefilled syringes, liquid and lyophilised vials (large-scale commercial) EU GMP, 12 international health authorities
Livron France Sterile ampoules, suppositories EU GMP, ANSM, ANSES, KFDA

How Adragos Pharma Supports Technology Transfer in Practice

Semi-Solid and Non-Sterile Liquid Manufacturing: Adragos Leipzig, Germany

The Leipzig facility was founded in 1926 and operates across 13,300 m² of production area. The site holds EU GMP certification for both human and animal pharmaceutical products and specialises in semi-solid and non-sterile liquid manufacturing.

For semi-solid products, two production lines equipped with Marchesini and Norden machinery support batch sizes from 15 to 1,250 litres across creams, gels, ointments and healing pastes. Packaging capability includes aluminium tubes (2 g to 150 g), plastic tubes (25 g to 200 g) and laminate tube formats. For non-sterile liquid products, three production lines (Dovema, Groninger and Würschum) support batch sizes of up to 4,000 litres. Plastic and glass bottle formats from 20 mL to 700 mL are available. The site also handles controlled substances.

Technology transfer services at Leipzig encompass:

  • Galenical development and transfer management
  • Pilot batch manufacture
  • Global raw material procurement
  • Production and secondary packaging
  • Analytical and batch release testing, including method transfer
  • Stability studies for ICH climate zones II, IVa and IVb
  • Process validation and product quality reviews
  • Serialisation in accordance with the EU Falsified Medicines Directive
  • Qualified Person-certified batch release, including for clinical investigational medicinal products

Analytical capabilities include HPLC, Gas Chromatography (GC), GC headspace analysis, ultraviolet-visible spectrophotometry and titration.

Clinical and Commercial Sterile Fill-and-Finish: Adragos Jura, Switzerland

The Jura facility has more than 25 years of specialisation in aseptic fill-and-finish for liquid and lyophilised vials, serving both clinical trial material programmes and small-to-medium scale commercial supply. The site is certified by the EMA, the FDA and Swissmedic, and produces approximately 200 clinical batches per year across a broad client base ranging from large pharmaceutical companies through to early-stage biotechnology firms.

There is no minimum batch size restriction; lyophiliser capacity accommodates up to 74,400 vials across freeze-dryers of 3 m² and 9 m² capacity. Vial formats range from 2R to 30R. The site operates RABS for aseptic processing, supports both peristaltic and rotary piston filling pumps and uses a single-use strategy that reduces cleaning validation burden and cross-contamination risk. A standard turnaround from order to batch is three months, including for programmes involving controlled substance handling.

Technology transfer at Jura is supported across the following stages:

  • Technical and GMP feasibility assessment
  • Preclinical material preparation and toxicology study support
  • Pilot batch manufacture and process alignment
  • Full GMP manufacturing, secondary packaging and clinical kit preparation
  • GMP storage and temperature-controlled shipment of analytical samples
  • Long-term stability storage and testing under ICH conditions

Analytical services include HPLC validation, sterility suitability testing, endotoxin suitability testing and bioburden suitability testing.

Large-Scale Commercial Injectable Manufacturing: Adragos Maisons-Alfort, France

For programmes transitioning from clinical to high-volume commercial injectable supply, the Maisons-Alfort facility in France provides large-scale sterile manufacturing with over 77 years of operational experience. The site holds EU GMP certification and is certified by 12 international health authorities.

Two filling lines equipped with RABS produce prefilled syringes at up to 540 units per minute, with an annual capacity of 150 million units across three syringe formats: Standard, Preventis™ and Eris™. For liquid and lyophilised vials, a single filling line operates at up to 300 vials per minute, supported by two large automated loading and unloading freeze-dryers accommodating up to 74,000 vials. Automated inspection is performed by two Seidenader lines at up to 600 units per minute. The site operates with Clean-In-Place and Sterilise-In-Place systems and provides fully compliant Aseptic Process Simulation services.

Ampoule and Suppository Manufacturing: Adragos Livron, France

The Livron facility, with over 110 years of manufacturing experience, specialises in sterile liquid ampoules and suppositories. Four production lines, two equipped with RABS for aseptic filling and two for terminal sterilisation by heat, provide an annual ampoule capacity of 120 million units. Batch sizes range from 30 to 1,500 litres across ampoule formats from 1 mL to 10 mL. Three fully automated visual inspection lines provide optical, cosmetic and pinhole detection. For suppositories, two filling machines and a packaging line accommodate batch sizes from 100 kg to 2,000 kg, producing suppositories and ovules from 0.9 g to 46 g. Controlled substance handling is available across both product formats.

Selecting the Right Site for Your Technology Transfer Programme

When evaluating CDMO services for a technology transfer programme, site selection should be driven by dosage form expertise, available batch scale, analytical capability and the regulatory certifications required for the target markets. A CDMO operating a network of complementary sites, each with validated capability in its specialist dosage form, provides the additional advantage of continuity: a product can progress from clinical trial material manufacturing through to large-scale commercial supply without the regulatory and operational disruption of changing partner.

Adragos Pharma’s European manufacturing network, spanning Leipzig, Jura, Maisons-Alfort and Livron, provides this continuity across semi-solid, non-sterile liquid and sterile injectable dosage forms. For programmes requiring access to the Japanese market, the Kawagoe facility provides visual inspection and packaging services aligned with the stringent requirements of Japan’s Ministry of Health, Labour and Welfare and the PMDA, acting as a final quality gateway for products entering Japan from European or United States manufacturing sites.

To discuss how the Adragos Pharma manufacturing network can support your technology transfer programme, contact the Adragos team directly.

Frequently Asked Questions

What is technology transfer in pharmaceutical manufacturing?

Technology transfer in pharmaceutical manufacturing is the structured, documented process by which a product’s formulation, manufacturing method and quality control procedures are formally conveyed from an originating organisation to a receiving manufacturing site. It is governed by international frameworks including ICH Q8, Q10 and Q11 guidelines and requires formal documentation, analytical method transfer, pilot batch manufacture and process validation at the receiving site before commercial production can commence.

What are the key steps in a CDMO technology transfer for semi-solid and injectable products?

The key steps are: technical feasibility assessment and gap analysis; technical package review and documentation transfer; analytical method transfer; pilot batch manufacture; process validation and scale-up; and transition to commercial supply with Continued Process Verification. Each stage must be formally completed and reviewed before the next begins. The entire programme is underpinned by a Technology Transfer Protocol agreed upon at the outset and a Transfer Report produced at its conclusion.

What GMP regulations apply to technology transfer in Europe?

In Europe, technology transfer activities are governed by the EU GMP guidelines, specifically Chapter 6 (Quality Control), Chapter 7 (Outsourced Activities) and Annex 15 (Qualification and Validation). EMA guidance on technology transfer provides additional procedural requirements. All manufacturing stages require oversight and batch certification by a Qualified Person.

What is the difference between a technology transfer for semi-solid and injectable products?

Semi-solid technology transfer focuses primarily on controlling rheological behaviour, mixing uniformity, homogenisation efficiency and scale-dependent heat transfer. Injectable technology transfer requires sterility assurance through validated aseptic process design, container closure integrity evaluation and, for lyophilised products, freeze-dryer cycle characterisation at the receiving site. Injectable transfers also carry more complex regulatory variation requirements due to the sterile classification of the product and the greater number of critical process parameters involved.

What documentation is required for a pharmaceutical technology transfer?

Required documentation from the sending organisation includes master batch records, process descriptions, analytical methods, raw material specifications, stability data, regulatory dossier summaries and validation reports. The receiving site must produce a formal Technology Transfer Protocol, transfer study reports, analytical method transfer reports and, following pilot batch manufacture, a process validation plan and report. All documentation must meet the standards required by the relevant regulatory authorities for the target markets.

Does Adragos Pharma support both clinical and commercial scale technology transfer?

Yes. Adragos Pharma supports technology transfer programmes at both clinical and commercial scale. The Jura facility in Switzerland handles clinical trial material manufacturing with no minimum batch size restriction and a standard three-month turnaround from order to batch, including for controlled substance programmes. Maisons-Alfort in France provides large-scale commercial sterile fill-and-finish for prefilled syringes and vials. Leipzig in Germany offers semi-solid and non-sterile liquid manufacturing from 15 litres through to 4,000 litres at commercial scale.

What analytical methods are available to support technology transfer at Adragos facilities?

At Adragos Leipzig, analytical methods include HPLC, GC, GC headspace analysis, ultraviolet-visible spectrophotometry and titration, alongside microbiological testing including Total Aerobic Microbial Count and Total Yeast and Mould Count determination. At Adragos Jura, available methods include HPLC validation, sterility suitability testing, endotoxin suitability testing and bioburden suitability testing. Method development, validation and formal transfer are included within the analytical service offering at both sites.

Does Adragos Pharma handle controlled substances during technology transfer?

Yes. Adragos Leipzig handles controlled substances for semi-solid and non-sterile liquid products. Adragos Jura includes controlled drug handling within its standard three-month order-to-batch turnaround for sterile injectable programmes. Adragos Livron also handles controlled substances for ampoule and suppository manufacturing.

What stability testing zones are supported across the Adragos network?

Adragos Leipzig provides stability testing for ICH climate zones II, IVa and IVb, with alarm-controlled temperature and humidity monitoring and a computer-aided scheduling and data management system. Studies are available during both clinical development and post-approval stages. Adragos Jura provides long-term stability storage under ICH conditions, with analytical testing at intermediate and final stability time points, covering the full product lifecycle from development through distribution.

How does Adragos Pharma support market entry into Japan?

Adragos Pharma supports Japanese market entry through its Kawagoe facility in Japan, which provides visual inspection and packaging services to meet the stringent quality requirements of Japan’s Ministry of Health, Labour and Welfare and the PMDA. For pharmaceutical companies manufacturing at European or United States sites, Adragos can manage bulk preparation at the relevant Adragos facility and transfer products to Kawagoe for final visual inspection and packaging in Japan, supporting both co-marketing and Designated Marketing Authorisation Holder arrangements.


]]>
https://adragos-pharma.com/cdmo-tech-transfer-semi-solids-injectables/feed/ 0
How to Audit a Sterile Injectable CDMO in 2026 https://adragos-pharma.com/how-to-audit-a-sterile-injectable-cdmo/ https://adragos-pharma.com/how-to-audit-a-sterile-injectable-cdmo/#respond Tue, 07 Jul 2026 15:45:45 +0000 https://adragos-pharma.com/?p=26219 Choosing the right sterile injectable CDMO is one of the highest stakes decisions a pharmaceutical or biotech team will make, and a rigorous audit is how you reduce the risk. A sterile injectable CDMO audit examines fill-finish operations, quality systems, Chemistry, Manufacturing and Controls (CMC) documentation, and inspection readiness across the full path from clinical batches to commercial supply. This 2026 guide walks development and operations leaders through what to assess, what evidence to request, and the questions that separate a compliant partner from a risky one.

What does a sterile injectable CDMO audit cover?

A sterile injectable CDMO audit is a structured evaluation of a Contract Development and Manufacturing Organization (CDMO) that fills and finishes sterile drug products. It confirms that the site can manufacture your product safely, at the required scale, and in full regulatory compliance. A complete audit covers five areas:

  • Fill-finish operations and aseptic technology.
  • Quality systems and regulatory certifications.
  • CMC documentation and regulatory submissions.
  • Inspection readiness and audit history.
  • Capacity and the ability to scale from clinical to commercial supply.

Fill-finish operations to assess

Fill-finish is where a sterile product is most exposed to contamination risk, so it deserves the closest attention. Confirm that the site runs aseptic filling within a Restricted Access Barrier System (RABS) or isolator, with a Class A critical zone surrounded by a Class B environment. Ask which dosage formats the site can fill, and match them to your product presentation:

  • Liquid and lyophilised vials for small molecules and biological products.
  • Prefilled syringes for ready-to-use presentations.
  • Ampoules with aseptic or terminal sterilisation.
  • Sterile liquids in vials, or in intravenous bags produced with Blow-Fill-Seal (BFS) technology.

Also confirm that the site holds a current, fully compliant Aseptic Process Simulation (APS), which is the media fill that demonstrates the line can maintain sterility. Across our European network, we cover this full range: liquid and lyophilised vials at our Jura site in Switzerland, prefilled syringes and vials at our Maisons-Alfort site in France, ampoules with aseptic and terminal sterilisation at our Livron site in France, and Blow-Fill-Seal intravenous bags and ampoules at our Halden site in Norway.

Quality systems and certifications to check

Certifications tell you which markets a site can legally supply. For sterile injectables sold in the major regulated markets, look for European Union Good Manufacturing Practice (EU-GMP), United States Food and Drug Administration approval, and, for Swiss sites, Swissmedic certification. Review the site against the revised European Union Good Manufacturing Practice Annex 1 on the manufacture of sterile medicinal products, and ask to see its contamination control strategy. You can review the current framework on the European Medicines Agency good manufacturing practice pages.

Our sites carry the certifications required for global supply. Our Jura site holds EU-GMP, United States Food and Drug Administration approval and Swissmedic certification. Our Maisons-Alfort site is certified by twelve international health authorities and reports an outstanding audit record. Our Halden site holds EU-GMP and United States Food and Drug Administration approval alongside authorities in Brazil, Japan and China, and supplies more than seventy-five countries.

CMC documentation and regulatory submissions

A strong CDMO does more than fill vials. It gives you the documentation that supports your regulatory filings. During the audit, confirm that the site can provide a complete technology transfer package, process validation data, and ongoing stability studies. Ask how it supports United States Food and Drug Administration and European Medicines Agency submissions, and whether it can compile documentation in electronic Common Technical Document (eCTD) format. Clear, submission-ready CMC documentation is what keeps a clinical to commercial timeline on track. The United States Food and Drug Administration guidance on sterile drug products produced by aseptic processing is a useful reference for the standards a site should meet.

Inspection readiness from clinical to commercial supply

Inspection readiness is the clearest signal of a mature quality culture. Ask for the site regulatory inspection history, its record of critical and major findings, and how it manages deviations and Corrective and Preventive Actions (CAPA). A site that can show a clean, well-documented inspection history is far less likely to disrupt your supply. Our Maisons-Alfort site, for example, reports that one hundred per cent of its inspection actions have been closed with zero critical findings.

Capacity and scaling from clinical to commercial supply

Your CDMO needs to fit both where your product is today and where it is going. For early programmes, ask whether the site accepts small or limited-quantity batches, since many sterile products begin with high-value, low-volume clinical material. For commercial supply, confirm batch sizes, annual capacity and continuity of supply. Our Jura site, for example, applies no minimum batch size and can fill up to 74,400 vials, with a three-month response from order to batch, which suits products moving from clinical trial materials through to commercial manufacturing. For higher volumes, our Maisons-Alfort site produces more than 130 million units per year with large-scale freeze-drying of up to 70,000 vials.

Sterile injectable CDMO audit checklist

Use this short checklist to structure your next audit:

  • Does the site run aseptic filling within a Restricted Access Barrier System or isolator, with Class A in Class B environments?
  • Does it hold a current, fully compliant Aseptic Process Simulation?
  • Does it fill the dosage format your product needs?
  • Does it hold EU-GMP, United States Food and Drug Administration approval and any market-specific certifications you require?
  • Can it provide a full technology transfer package and process validation data?
  • Does it support United States Food and Drug Administration and European Medicines Agency submissions in electronic Common Technical Document format?
  • What is its regulatory inspection history and record of critical findings?
  • Can it scale from clinical batches to commercial supply without a change of site?

How Adragos supports sterile injectable manufacturing

We offer sterile injectable manufacturing across four European sites, each with its own specialisation, so a product can be matched to the right technology rather than forced onto a single line:

  • Jura, Switzerland: aseptic fill-finish of liquid and lyophilised vials for small molecules and biological products, with no minimum batch size and EU-GMP, United States Food and Drug Administration and Swissmedic certification.
  • Maisons-Alfort, France: prefilled syringes and liquid and lyophilised vials, with high-speed aseptic filling, large-scale freeze-drying and automated inspection.
  • Livron, France: ampoules with aseptic and terminal sterilisation, plus suppositories, with more than one hundred molecules handled.
  • Halden, Norway: sterile liquids in intravenous bags and ampoules produced with Blow-Fill-Seal technology, supplying more than seventy-five countries.

Together our sites cover the full path from clinical trial materials to commercial supply. To discuss a specific programme, contact our sterile injectable team.

Frequently asked questions

What is a sterile injectable CDMO?

A sterile injectable CDMO is a Contract Development and Manufacturing Organization that develops, fills and finishes sterile products given by injection, such as vials, prefilled syringes and ampoules, under Good Manufacturing Practice conditions.

What certifications should a sterile injectable CDMO hold?

At a minimum, look for European Union Good Manufacturing Practice and, where you supply the United States, United States Food and Drug Administration approval. Swiss sites should also hold Swissmedic certification, and additional national approvals matter if you supply markets such as Japan, Brazil or China.

How do I move a sterile injectable from clinical to commercial supply?

Choose a CDMO that can support both stages, provide a clear technology transfer package, and scale batch sizes without a change of site. This continuity avoids repeating validation and protects your timeline.

What is Aseptic Process Simulation?

Aseptic Process Simulation, also called a media fill, replaces the product with a sterile growth medium to prove that the filling line can maintain sterility. A current, fully compliant simulation is a core requirement for any sterile injectable CDMO.

]]>
https://adragos-pharma.com/how-to-audit-a-sterile-injectable-cdmo/feed/ 0
How to Scale Semi-Solid and Liquid Drug Production https://adragos-pharma.com/semi-solid-and-liquid-drug-production/ https://adragos-pharma.com/semi-solid-and-liquid-drug-production/#respond Fri, 03 Jul 2026 08:46:32 +0000 https://adragos-pharma.com/?p=25494 Scaling semi-solid and liquid pharmaceutical products from development batches to commercial volumes requires a disciplined sequence of technology transfer, equipment qualification and process validation activities. For creams, ointments, gels, suspensions, solutions and syrups, the rheological behaviour, homogeneity and microbiological control that are straightforward at laboratory scale become significantly more complex once batch sizes increase. This guide outlines the structured approach used by experienced Contract Development and Manufacturing Organisations to move products through pharmaceutical manufacturing scale-up without compromising quality, regulatory compliance or supply continuity.

What Does Scaling Semi-solid and Liquid Drug Production Involve?

Pharmaceutical manufacturing scale-up is the process of transferring a formulation from development or pilot scale to a qualified commercial production environment, then validating that the process consistently delivers product meeting predefined specifications. For semi-solids and liquids, this typically involves four sequential phases: process development, technology transfer, engineering and validation batches, and routine commercial manufacturing. Each phase has defined deliverables and acceptance criteria that must be met before the next phase begins.

Phase 1: Pharmaceutical Process Development

Before scale-up can begin, the formulation and the manufacturing process must be sufficiently characterised. At this stage, development teams define the critical quality attributes of the product and identify the critical process parameters that influence them. For semi-solids, these often include mixing speed, shear rate, temperature ramp profiles, homogenisation duration and cooling rates. For liquid products, parameters such as order of addition, dissolution time, filtration strategy and bioburden control typically dominate.

Robust process development should produce:

  • A documented manufacturing process description.
  • Defined critical quality attributes and critical process parameters.
  • Analytical methods suitable for routine release testing.
  • Stability data supporting the proposed shelf life.
  • A risk assessment identifying potential scale-up challenges.

Without this foundation, downstream technology transfer activities carry significant risk of failure.

Phase 2: Technology Transfer

Technology transfer is the structured movement of product, process and analytical knowledge from a sending site, often the originator’s laboratory or a pilot facility, to the receiving commercial manufacturing site. A well-executed transfer reduces the likelihood of deviations during validation and accelerates time to first commercial batch.

Key Technology Transfer Deliverables

  1. Transfer protocol and project plan defining scope, responsibilities, timelines and success criteria.
  2. Gap analysis comparing the sending site’s equipment, utilities and analytical capabilities with those of the receiving site.
  3. Raw material and packaging component qualification to confirm that suppliers, grades and specifications are aligned.
  4. Analytical method transfer including method verification or co-validation to demonstrate equivalent performance at the receiving site.
  5. Process fit assessment to confirm that vessel geometry, mixer design, heat transfer capacity and filling equipment are appropriate for the formulation.

For semi-solid and liquid products, equipment differences between scales are particularly important. Mixing dynamics, heat transfer surface area to volume ratios and shear profiles do not scale linearly, and these differences must be modelled or empirically tested before engineering batches commence.

Phase 3: Engineering and Validation Batches

Once the transfer is complete, manufacturing trials begin at commercial scale.

Engineering Batches

Engineering batches are non-Good Manufacturing Practice or partially compliant runs used to refine the process at full scale. They allow operators to confirm equipment settings, sequence timing, in-process control sampling points and cleaning procedures before committing to validation. For semi-solids, engineering batches frequently reveal differences in cooling profiles or air entrainment that require process adjustment.

Process Performance Qualification

Process Performance Qualification, the second stage of process validation as defined by the European Medicines Agency and the United States Food and Drug Administration, demonstrates that the commercial process operates reproducibly. Typically, three consecutive successful batches manufactured under routine conditions are required, with comprehensive sampling and testing against predefined acceptance criteria.

For liquid production scaling, validation should specifically address:

  • Content uniformity across the batch and throughout the filling run.
  • Microbiological control, including hold times and bioburden limits before sterilising filtration where applicable.
  • Container closure integrity.
  • Stability of validation batches under International Council for Harmonisation conditions.

For semi-solid manufacturing, additional attention is given to:

  • Homogeneity of Active Pharmaceutical Ingredient distribution within the matrix.
  • Viscosity and rheological consistency across the batch.
  • Tube or jar fill weight uniformity.
  • Visual appearance and absence of phase separation.

Phase 4: Commercial Drug Production

Following successful Process Performance Qualification, the product enters routine commercial manufacturing under the continued process verification framework. This third stage of validation requires ongoing monitoring of process performance to detect drift, support continuous improvement and maintain a state of control. Trending of critical process parameters and critical quality attributes is documented in periodic product quality reviews.

Lifecycle management also includes change control for any modification to equipment, suppliers, batch size or process parameters, with each change assessed for revalidation requirements.

Common Scale-Up Challenges for Semi-solids and Liquids

Even with rigorous planning, certain scale-up challenges recur across semi-solid and liquid programmes:

  • Mixing and shear differences between pilot and commercial vessels affecting emulsion stability or particle size distribution.
  • Heat transfer limitations in larger jacketed vessels producing different cooling profiles, which can alter crystallisation or viscosity.
  • Air incorporation during high-shear mixing leading to product defects in semi-solids.
  • Hold time impacts on bioburden, viscosity or chemical stability of bulk product before filling.
  • Filling line compatibility with viscous or shear-sensitive formulations.
  • Cleaning validation complexity for products with low solubility or strong colour.

Anticipating these issues during process development and addressing them in the transfer protocol significantly reduces validation risk.

How Adragos Pharma Supports Semi-solid and Liquid Scale-Up

Adragos Pharma operates dedicated facilities for the development and commercial manufacture of liquid and semi-solid pharmaceutical products, including its site in Leipzig, Germany, which specialises in these dosage forms. The company supports clients across the full scale-up pathway, from formulation development and analytical method transfer through engineering batches, Process Performance Qualification and routine commercial supply. Integrated quality, regulatory and supply chain teams manage technology transfer projects under defined governance structures, with the objective of delivering predictable timelines and validated commercial processes.

Key Takeaways for Development Leaders

  • Pharmaceutical manufacturing scale-up should follow four structured phases: development, technology transfer, engineering and validation, and commercial production.
  • Critical quality attributes and critical process parameters must be defined before transfer begins.
  • Equipment differences in mixing, shear and heat transfer are the most common sources of scale-up challenges for semi-solids and liquids.
  • Process Performance Qualification typically requires three consecutive successful batches under routine conditions.
  • Continued process verification maintains the validated state throughout the commercial lifecycle.
  • Selecting a Contract Development and Manufacturing Organisation with proven experience in semi-solid and liquid dosage forms, qualified equipment trains and an established technology transfer methodology is one of the most effective ways to reduce timeline risk in commercial drug production.

Frequently Asked Questions

What are the phases of scaling semi-solid and liquid drug production?

Scaling semi-solid and liquid drug production follows four sequential phases: pharmaceutical process development, technology transfer, engineering and validation batches, and routine commercial production. Each phase has defined deliverables and acceptance criteria that must be met before the next phase begins.

How many batches are required for Process Performance Qualification?

Process Performance Qualification typically requires three consecutive successful batches manufactured under routine commercial conditions, with comprehensive sampling and testing against predefined acceptance criteria.

What are the most common scale-up challenges for semi-solids and liquids?

The most common challenges are equipment-related: differences in mixing and shear between pilot and commercial vessels, heat transfer limitations in larger jacketed vessels, air incorporation during high-shear mixing, hold time impacts on bulk product, filling line compatibility with viscous formulations, and cleaning validation complexity. These differences do not scale linearly and should be modelled or tested before engineering batches.

Why is technology transfer important in pharmaceutical scale-up?

Technology transfer is the structured movement of product, process and analytical knowledge from the sending site to the receiving commercial site. A well-executed transfer reduces the likelihood of deviations during validation and accelerates time to first commercial batch.

]]>
https://adragos-pharma.com/semi-solid-and-liquid-drug-production/feed/ 0
How to Scale Semisolid and Liquid Drug Products From Development to Commercial Manufacturing https://adragos-pharma.com/semisolid-liquid-manufacturing-scale-up-pharma/ https://adragos-pharma.com/semisolid-liquid-manufacturing-scale-up-pharma/#respond Thu, 02 Jul 2026 11:57:44 +0000 https://adragos-pharma.com/?p=26125 Scaling Semisolids & Liquids in Pharma | Adragos

Scaling semisolid and liquid pharmaceutical products from laboratory to commercial manufacturing requires a systematic progression through formulation development, pilot batch production, process validation and technology transfer. Each stage introduces new critical process parameters that must be understood and controlled before advancing to the next. Adragos Leipzig, a European Union Good Manufacturing Practice-certified contract manufacturing facility with over 100 years of production experience, supports drug developers across this entire journey, from early formulation work through to high-volume commercial supply.

What Scaling a Semisolid or Liquid Product Actually Involves

Pharmaceutical manufacturing scale-up is not simply a matter of increasing batch size. As a product moves from a laboratory bench to a commercial production line, the physical and chemical conditions governing mixing, heat transfer and shear forces change considerably. These changes can affect the homogeneity of a cream, the droplet size distribution of an emulsion, the dissolution rate of a suspension or the viscosity profile of a gel.

For semisolid products including creams, gels, ointments and healing pastes, the critical challenges at scale are thermal management during heating and cooling phases, homogenisation efficiency and deaeration. For non-sterile liquid products including solutions, drops, suspensions and emulsions, the key considerations are mixing uniformity, particle size consistency, dissolution kinetics and pH stability at larger volumes.

Understanding these distinctions from the outset determines how successfully a product transitions through each manufacturing stage.

Stage One: Formulation Development and Recipe Optimisation

The first step in any scale-up programme is establishing a robust formulation at laboratory scale. This involves identifying the active pharmaceutical ingredient concentration, excipient system, pH target, physical form and processing conditions that together produce the desired product quality attributes.

At this stage, the formulation team develops tailor-made formulations by evaluating different excipient combinations and manufacturing approaches. The objective is to identify a recipe that is not inherently sensitive to small changes in process conditions, a principle aligned with design space definition under International Council for Harmonisation Q8 guidelines.

Adragos Leipzig conducts this work as part of its galenical development service, which encompasses recipe development, manufacturing process optimisation and the preparation of the first pilot batch at laboratory scale.

Stage Two: Pilot Batch Production

Once a formulation has been established at laboratory scale, the next step is to produce pilot batches at an intermediate volume. Pilot batches serve two purposes. First, they allow the manufacturing team to confirm that the formulation behaves consistently at larger volumes. Second, they generate product and process data that informs the process validation strategy.

At Adragos Leipzig, semisolid development begins at batch sizes from 15 litres, progressing in a controlled manner towards commercial-scale production volumes. During pilot batch manufacture, the team documents critical process parameters including:

  • Mixing speed and duration
  • Heating and cooling temperature profiles
  • Homogenisation intensity and time
  • Deaeration conditions
  • In-process control results

These parameters form the basis of the batch record that will be used for process validation and, subsequently, for routine commercial production.

Stage Three: Process Validation

Process validation is the documented evidence that a manufacturing process consistently produces a product meeting its predetermined specifications and quality attributes. Regulatory authorities including the European Medicines Agency and the United States Food and Drug Administration require process validation before a product can enter commercial sale.

For semisolid and liquid products, process validation typically involves the manufacture of a defined number of consecutive batches at commercial scale under the conditions described in the product’s regulatory submission. The validation protocol specifies acceptance criteria for critical quality attributes such as viscosity, pH, content uniformity, microbial limits and physical appearance.

Adragos Leipzig provides validation of manufacture as a defined service, alongside the creation of product quality reviews, ensuring the validation programme meets both European Union and international regulatory requirements.

Stage Four: Technology Transfer to Commercial Manufacturing

Technology transfer is the formal process by which the formulation, manufacturing process and analytical methods developed at one scale or one site are transferred to the commercial manufacturing environment. A well-executed technology transfer ensures that nothing critical is lost in the transition and that the commercial site can reproduce the process with full understanding of its parameters and constraints.

At Adragos Leipzig, technology transfer and galenical development are managed as an integrated service. This includes transfer management, analytical method transfer with full documentation and batch release procedures carried out by a Qualified Person. Serialisation in compliance with the European Union Falsified Medicines Directive is included as part of the commercial manufacturing service.

Critical Process Parameters for Semisolids and Liquids

Understanding which process parameters are critical, and how they behave at different scales, is central to a successful scale-up programme. The table below summarises the key parameters by dosage form.

Dosage Form Critical Process Parameters
Creams and emulsions Temperature during emulsification, mixing speed, homogeniser intensity, cooling rate
Gels Polymer hydration time and temperature, mixing uniformity, pH adjustment
Ointments Temperature of active pharmaceutical ingredient incorporation, mixing time, batch homogeneity
Solutions Dissolution time, mixing speed, pH stability, hold time
Suspensions Particle size distribution, mixing uniformity, settling behaviour
Emulsions Droplet size distribution, emulsification energy input, temperature profile

At larger scales, heat transfer and mixing efficiency differ substantially from laboratory conditions. A homogeniser that produces a specific shear profile at 50 litres will not replicate that profile identically at 1,000 litres. Understanding this scaling factor and compensating for it through equipment selection and process parameter adjustment is the core technical challenge of pharmaceutical manufacturing scale-up.

Equipment Selection and Its Role in Scalable Manufacturing

Equipment selection has a direct bearing on whether a product scales successfully. The choice of mixing vessel geometry, homogeniser type, pump configuration and heat exchanger capacity all influence product quality at commercial scale.

Adragos Leipzig operates two semisolid production lines equipped with Marchesini and Norden machinery, supported by an EKATO mixing tank. For non-sterile liquid products, three dedicated production lines utilise Dovema, Würschum and Groninger equipment, with batch capacities reaching up to 4,000 litres.

Commercial container formats available at Leipzig include:

  • Semisolids: laminate and plastic tubes (25 g to 200 g) and aluminium tubes (2 g to 150 g)
  • Non-sterile liquids: plastic and glass bottles from 20 mL to 700 mL

Having access to commercial-scale equipment during development and pilot batch phases means that process parameters established at smaller scales can be translated into commercial manufacturing conditions with greater confidence.

Analytical Testing and Quality Control Throughout Scale-Up

Robust analytical testing is required at every stage of the scale-up process, from raw material release through in-process control to finished product batch release. Analytical methods must be fit for purpose at each scale and must be formally transferred when production moves to a new scale of operation.

Adragos Leipzig’s quality control laboratory supports routine analytics including:

  • Raw material analysis of active pharmaceutical ingredients and excipients
  • Bulk and finished product analysis
  • Batch release testing for solid, liquid and semisolid formulations
  • Residual solvent investigation
  • Microbiology testing including Total Aerobic Microbial Count and Total Yeast and Mould Count determination

Techniques available include High-Performance Liquid Chromatography, Gas Chromatography, Gas Chromatography headspace analysis, ultraviolet-visible spectroscopy and titration. Method development, validation and formal transfer are included within the analytical service offering.

Stability Studies at Scale

Stability testing confirms that a product remains within its specification throughout its proposed shelf life under the storage conditions relevant to its target markets. As batch size increases through scale-up, stability data generated at smaller scales must be supplemented with data from commercial-scale or pilot-scale batches.

Adragos Leipzig operates stability chambers covering International Council for Harmonisation climate zones II, IVa and IVb, with alarm-controlled monitoring of temperature and humidity and a computer-aided scheduling and data management system. Stability studies are offered during both clinical development and post-approval stages.

How Adragos Leipzig Supports Scale-Up From 15 Litres to 4,000 Litres

Adragos Leipzig provides a fully integrated contract development and manufacturing service for semisolid and non-sterile liquid products. With a production area of 13,300 square metres and over 100 years of manufacturing heritage, the facility brings together galenical development expertise, pilot batch capability, commercial-scale production and analytical support under a single European Union Good Manufacturing Practice-certified operation.

The full service scope at Leipzig includes:

  • Galenical formulation development and recipe optimisation
  • Pilot batch production and process development
  • Technology transfer management
  • Analytical method development, validation and transfer
  • Process validation and product quality reviews
  • Stability studies across International Council for Harmonisation climate zones
  • Commercial manufacture with Qualified Person batch certification
  • Serialisation in compliance with the European Union Falsified Medicines Directive
  • Secondary packaging and controlled drug handling

The facility holds European Union Good Manufacturing Practice certification for both human and animal pharmaceutical products, accommodating a broad range of product types from specialised pharmaceutical formulations through to cosmetic-adjacent topical preparations. Leipzig operates as part of the wider Adragos Pharma global network, which spans seven Good Manufacturing Practice-certified facilities across Europe and Japan.

To discuss your semisolid or liquid scale-up programme with the Adragos Leipzig team, contact us here.

Frequently Asked Questions

What is the difference between scaling a semisolid and a liquid pharmaceutical product?

The core challenge for semisolids lies in controlling homogenisation, temperature and shear at increasing batch sizes. For non-sterile liquids, the primary concerns are mixing uniformity, dissolution rate and, for suspensions, particle size distribution. Both require careful evaluation of critical process parameters at each transition point in the scale-up journey.

What batch sizes are available for semisolid scale-up at Adragos Leipzig?

Semisolid batch sizes at Adragos Leipzig range from 15 litres up to 1,250 litres across two production lines equipped with Marchesini and Norden machinery. Non-sterile liquid batches can be produced at volumes up to 4,000 litres across three production lines.

What stability zones are supported at Adragos Leipzig?

Adragos Leipzig supports stability testing under International Council for Harmonisation climate zone II, IVa and IVb conditions. Chambers are fitted with alarm-controlled monitoring of temperature and humidity and are managed through a computer-aided scheduling and data management system. Stability studies are available during clinical development and post-approval stages.

What analytical methods are used during scale-up at Adragos Leipzig?

Available analytical methods include High-Performance Liquid Chromatography, Gas Chromatography, Gas Chromatography headspace analysis, ultraviolet-visible spectroscopy and titration. Microbiological testing, including Total Aerobic Microbial Count and Total Yeast and Mould Count determination, is also available. Method development, validation and formal transfer are included within the analytical service offering.

Does Adragos Leipzig offer batch certification by a Qualified Person?

Yes. Batch certification by a Qualified Person is included as part of the commercial manufacturing service at Adragos Leipzig, alongside serialisation in compliance with the European Union Falsified Medicines Directive.

Does Adragos Leipzig handle controlled drugs?

Yes. Adragos Leipzig has controlled drug handling capability, supporting a range of product types from standard pharmaceutical formulations through to products requiring additional regulatory controls.

What is the GMP certification status of Adragos Leipzig?

Adragos Leipzig holds European Union Good Manufacturing Practice certification for both human and animal pharmaceutical products. The facility was founded in 1926 and operates across a 13,300 square metre production area in eastern Germany.

]]>
https://adragos-pharma.com/semisolid-liquid-manufacturing-scale-up-pharma/feed/ 0
What Is Process Validation in Pharma Scale-Up https://adragos-pharma.com/process-validation-in-pharma-scale-up/ https://adragos-pharma.com/process-validation-in-pharma-scale-up/#respond Fri, 26 Jun 2026 12:21:33 +0000 https://adragos-pharma.com/?p=25887 Process validation is what turns a promising semi-solid or liquid formulation into a product that can be made reliably at commercial scale. This guide explains what process validation in pharma scale-up is, the three regulatory stages it follows, why scale-up needs dedicated validation work, and how a Contract Development and Manufacturing Organisation supports it across the lifecycle.

What Is Process Validation in Pharma Scale-Up?

Process validation in pharma scale-up is the documented evidence that a manufacturing process, when operated within defined parameters, consistently produces a medicinal product meeting its predetermined quality attributes. It is the regulatory and scientific framework that connects laboratory development to reliable commercial production, and it is particularly critical for semi-solid manufacturing and liquid formulation production, where rheology, homogeneity and microbiological control behave differently at larger batch sizes.

For development leaders moving a product from pilot to commercial scale, process validation is not a single event. It is a lifecycle that begins during process development and continues throughout the commercial life of the product.

The Three Stages of Process Validation

Regulatory authorities, including the European Medicines Agency and the United States Food and Drug Administration, recognise process validation as a three-stage lifecycle.

Stage 1: Process design

The commercial manufacturing process is defined based on knowledge gained from formulation development, pilot batches and risk assessment. Critical Quality Attributes and Critical Process Parameters are identified.

Stage 2: Process performance qualification

The designed process is confirmed at commercial scale through a defined number of consecutive batches that demonstrate reproducibility under routine manufacturing conditions.

Stage 3: Continued process verification

Ongoing monitoring of the commercial process ensures it remains in a state of control throughout the product lifecycle. Each stage produces documented evidence that supports regulatory submissions and routine batch release.

Why Scale-Up Requires Dedicated Validation Work

A formulation that performs consistently in a small development vessel will not automatically behave the same way in a large production vessel. Scaling introduces variables that are absent or negligible at small scale. Key challenges include the following.

  • Heat transfer rates change as vessel geometry changes, affecting emulsion stability in creams, ointments and gels.
  • Mixing energy and shear distribution differ across impeller designs and tank sizes, influencing particle size, viscosity and content uniformity.
  • Hold times between processing steps lengthen at commercial scale, which can affect microbiological control in aqueous liquid formulations.
  • Filling and packaging interfaces introduce additional variability that must be characterised.

Process validation addresses each of these variables by defining acceptable operating ranges and confirming that the product meets specification across the full range of expected manufacturing conditions.

Process Validation for Semi-Solid Manufacturing

Semi-solid manufacturing covers creams, ointments, gels and pastes. These products are sensitive to processing history, and small changes in mixing speed, temperature ramp rate or cooling profile can shift viscosity, active distribution or in-use performance. During scale-up, validation activities for semi-solids typically address the following.

  • Homogeneity of the Active Pharmaceutical Ingredient across the batch.
  • Globule or particle size distribution in emulsions and suspensions.
  • Rheological behaviour across replicate batches.
  • Microbiological quality and preservative efficacy at commercial hold times.
  • Container closure compatibility with the bulk product.

The objective is to confirm that the commercial process delivers the same in-vitro and in-use performance as the formulation qualified during process development.

Process Validation for Liquid Formulation Production

Liquid formulation production, including oral solutions, oral suspensions and topical liquids, requires validation focused on dissolution behaviour, suspension stability, fill weight accuracy and microbiological integrity. For suspensions, the resuspendability of the product after storage is a Critical Quality Attribute that must be verified across validation batches. For sterile or low-bioburden liquid products, validation also extends to the filtration step, sanitisation cycles and aseptic handling where applicable.

How Adragos Pharma Supports Validation Across the Lifecycle

Adragos Pharma supports pharmaceutical and biotech companies from early process development through commercial production. Its site in Leipzig, Germany manufactures semi-solid products, including creams, gels, ointments and healing paste, together with non-sterile liquids such as solutions, drops, suspensions and emulsions, under a European Union Good Manufacturing Practice quality system. Support across the validation lifecycle typically includes the following.

  • Formulation and process development with scale-up in mind from the earliest stages.
  • Risk-based identification of Critical Quality Attributes and Critical Process Parameters.
  • Engineering and pilot batches to characterise the process before commercial transfer.
  • Process Performance Qualification batches at commercial scale.
  • Analytical method validation to support release and stability testing.
  • Continued Process Verification programmes that maintain the state of control over the product lifecycle.

By integrating development and commercial manufacturing under a single quality system, the transfer between scales is shortened and the documentation chain remains consistent for regulatory submissions. To discuss a scale-up or validation project, prospective customers are encouraged to request a capability review.

What Development Leaders Should Plan For

Process validation is most efficient when it is designed into the project from the outset rather than added at the end of development. Development leaders preparing for commercial scale-up should plan for the following.

  • Early definition of Critical Quality Attributes and a target product profile.
  • A scientifically justified scale-up strategy that accounts for vessel geometry and mixing differences.
  • Sufficient analytical capacity to support validation batch testing.
  • A documented control strategy that links process parameters to product quality.
  • A continued process verification plan before the first commercial batch is released.

Each of these elements reduces the risk of failed validation batches and supports a smoother path to commercial supply.

Frequently Asked Questions

What is process validation in pharmaceutical scale-up?

Process validation is the documented evidence that a manufacturing process, run within defined parameters, consistently produces a product that meets its predetermined quality attributes. In scale-up it connects laboratory development to reliable commercial production.

What are the three stages of process validation?

The three stages are process design, process performance qualification and continued process verification. Together they define the process, confirm it at commercial scale and keep it in a state of control throughout the product lifecycle.

Why does semi-solid manufacturing need special validation at scale?

Creams, ointments and gels are sensitive to heat transfer, mixing energy and cooling profiles, all of which change with vessel size. Validation confirms that homogeneity, particle size and rheology remain within specification at commercial scale.

How does Adragos Pharma support process validation?

Adragos Pharma manages validation as an integrated lifecycle activity, from risk-based identification of Critical Quality Attributes through Process Performance Qualification and Continued Process Verification, with semi-solid and non-sterile liquid manufacturing at its site in Leipzig, Germany under a European Union Good Manufacturing Practice quality system.

]]>
https://adragos-pharma.com/process-validation-in-pharma-scale-up/feed/ 0
What Is Value Added Medicine in Specialty Pharma https://adragos-pharma.com/value-added-medicine-specialty-pharma/ https://adragos-pharma.com/value-added-medicine-specialty-pharma/#respond Fri, 26 Jun 2026 12:20:27 +0000 https://adragos-pharma.com/?p=25884 A value added medicine offers a practical route to a differentiated specialty product without the cost and risk of developing a new molecule. This guide explains what a value added medicine in specialty pharma is, why these products matter, the regulatory, manufacturing, market access and supply barriers involved, and how the right Contract Development and Manufacturing Organisation partner helps overcome them.

What Is a Value Added Medicine in Specialty Pharma?

A value added medicine is an existing, well characterised molecule that has been reformulated, repurposed or repositioned to deliver measurable clinical, patient or healthcare system benefits beyond those of the original product. In specialty pharmaceutical markets, a value added medicine sits between generics and new chemical entities, offering an evidence backed improvement, such as a modified release profile, a new route of administration, a fixed dose combination or an improved patient experience, without requiring the full development cycle of a novel Active Pharmaceutical Ingredient.

For developers, this category represents a defined commercial opportunity, but it also carries a distinct set of development and commercialisation barriers that differ from both generic and innovator pathways.

Why Value Added Medicines Matter in Specialty Markets

Specialty markets often serve smaller patient populations with complex therapeutic needs, including oncology, central nervous system disorders, rare diseases and chronic conditions managed in hospital or specialist settings. In these segments, incremental innovation can have a disproportionately positive impact on adherence, dosing accuracy and overall outcomes.

Value added medicines support several modern pharmaceutical business models, including lifecycle extension, portfolio diversification and entry into adjacent therapeutic niches without the capital intensity of new drug discovery. They are particularly relevant for small and mid sized companies pursuing niche therapies, where focused investment can yield differentiated products.

The Main Barriers to Developing Value Added Medicines

While the active substance may be known, the path to market is not a simple one. The principal challenges fall across four areas: regulation, manufacturing, market access and supply.

1. Regulatory complexity

Value added medicines do not fit neatly into either the generic abbreviated pathway or the full new drug application route. Developers must often pursue hybrid or 505(b)(2) style submissions with the United States Food and Drug Administration, or Article 10(3) applications in the European Union, each requiring tailored bridging studies, comparative bioavailability data and sometimes new clinical endpoints to demonstrate the added benefit. Key regulatory barriers include the following.

  • Demonstrating clinically meaningful differentiation versus the reference product.
  • Designing bridging or comparative studies acceptable to multiple agencies.
  • Managing intellectual property positioning around formulation patents.
  • Aligning paediatric, geriatric or special population requirements with the new product profile.

2. Manufacturing and technical barriers

Reformulation almost always introduces new technical demands. A modified release oral solid, a sterile injectable line extension or a transdermal version of an existing molecule each require specialised process capabilities, analytical methods and stability programmes. Common manufacturing barriers include the following.

  • Access to specialised dosage form technologies such as modified release oral solids, sterile fill and finish, semi-solid manufacturing or high-potency containment.
  • Scaling formulations from laboratory to commercial batches without altering the bioavailability profile.
  • Establishing robust analytical methods for new impurity profiles and dissolution behaviours.
  • Managing technology transfer between development partners and commercial manufacturing sites.

3. Market access and reimbursement

Even with a successful registration, reimbursement remains one of the most significant commercialisation hurdles for value added medicines. Health technology assessment bodies increasingly demand robust health economic evidence demonstrating that the incremental benefit justifies any price premium over the existing reference product. Specialty market strategies must therefore account for the following.

  • Early engagement with payers and health technology assessment bodies.
  • Real world evidence generation to support clinical differentiation claims.
  • Country by country variation in pricing and reimbursement frameworks.
  • Hospital formulary listing processes in specialist therapeutic areas.

4. Supply chain and commercial complexity

Specialty products typically operate at lower volumes than mass market generics but with higher quality, cold chain or controlled substance requirements. This creates a supply environment in which flexibility, reliability and regulatory coverage across multiple markets become decisive factors. Supply complexity challenges include the following.

  • Managing low to mid volume commercial batches economically.
  • Maintaining multi market regulatory compliance, including United States Food and Drug Administration, European Medicines Agency and Pharmaceuticals and Medical Devices Agency requirements.
  • Ensuring continuity of supply for products serving small but critical patient populations.
  • Coordinating serialisation, cold chain logistics and controlled substance handling where applicable.

How a CDMO Partnership Reduces These Barriers

For developers of specialty medicines, an integrated Contract Development and Manufacturing Organisation partner can compress timelines and reduce technical risk by combining formulation expertise, regulatory experience and commercial scale manufacturing under one quality system. The right partner offers the following.

  • Development and manufacturing of oral solids, sterile liquids, semi-solids and other specialty dosage forms.
  • Technology transfer services for products moving from innovator or legacy sites.
  • Multi site and multi region regulatory coverage to support global commercialisation.
  • A focus on small to mid volume specialty products that may not fit large generic manufacturing networks.

How Adragos Pharma Supports Value Added Medicine Development

Adragos Pharma develops value added medicines and other specialty products from its development centre in Athens, Greece, a site with more than twenty-five years of experience across generics, value added medicines and new chemical entities. The Athens team covers formulation development, analytical development, regulatory strategy and clinical and scientific support, including the handling of High-Potency Active Pharmaceutical Ingredients and controlled substances under appropriate containment.

Beyond development, the wider Adragos network manufactures across a broad range of dosage forms, including oral solids, semi-solid products, non-sterile liquids and sterile presentations, with sites in Germany, France and Japan operating under a unified Good Manufacturing Practice quality system. This integrated structure is designed to reduce the number of technology transfers across a product lifecycle and to give specialty developers a single accountable partner from early development through commercial supply.

To discuss a specialty or value added medicine project, prospective customers are encouraged to request a capability review.

Key Takeaways for Pharma and Biotech Developers

  • Value added medicines reformulate or reposition known molecules to deliver clinical, patient or system benefits.
  • They occupy a strategic position between generics and new chemical entities within specialty pharmaceutical markets.
  • The main barriers span hybrid regulatory pathways, specialised manufacturing requirements, reimbursement evidence and supply chain complexity.
  • Selecting a Contract Development and Manufacturing Organisation with proven specialty capability is central to managing technical and commercial risk.

Frequently Asked Questions

What qualifies a product as a value added medicine?

A value added medicine is based on a known Active Pharmaceutical Ingredient but offers a demonstrable improvement, such as a new formulation, route of administration, fixed dose combination or indication, supported by appropriate clinical or comparative data.

How do value added medicines differ from generics?

Generics replicate the reference product with equivalent bioavailability. Value added medicines intentionally differ from the reference product to provide added clinical, patient or healthcare system benefit, and therefore follow hybrid regulatory pathways.

Which dosage forms are most common for value added medicines?

Modified release oral solids, sterile injectables, semi-solids, transdermal systems and fixed dose oral combinations are among the most frequent formats used to deliver added value.

How can a CDMO support value added medicine projects?

A specialised Contract Development and Manufacturing Organisation provides formulation development, analytical method development, technology transfer and commercial manufacturing across the dosage forms required, while ensuring multi region regulatory compliance.

]]>
https://adragos-pharma.com/value-added-medicine-specialty-pharma/feed/ 0
How Semi-Solid and Liquid Scale-Up Works in Pharma https://adragos-pharma.com/semi-solid-and-liquid-scale-up/ https://adragos-pharma.com/semi-solid-and-liquid-scale-up/#respond Thu, 25 Jun 2026 10:49:10 +0000 https://adragos-pharma.com/?p=25510 Pharmaceutical scale-up for semi-solid and liquid products is the structured transfer of a formulation from laboratory or pilot scale to commercial manufacturing batches. The process requires alignment between formulation behaviour, equipment geometry, process parameters and quality controls, so that the product retains its critical quality attributes at every batch size. For developers, the scale-up phase often determines whether a candidate reaches market on its planned timeline.

This article explains how semi-solid and liquid scale-up is managed in a Contract Development and Manufacturing Organisation environment, what risks typically appear and how those risks are mitigated through technical transfer, equipment fit and regulatory readiness.

What Is Pharmaceutical Manufacturing Scale-Up?

Pharmaceutical manufacturing scale-up is the engineering and quality exercise of reproducing a developed formulation at progressively larger batch sizes while maintaining identical product performance. For semi-solids such as creams, ointments and gels, and for liquids such as solutions, suspensions and syrups, the central challenge is that mixing, heat transfer and shear forces do not scale linearly with vessel volume.

A successful scale-up programme produces a process that is:

  • Reproducible across multiple commercial batches.
  • Aligned with the validated control strategy.
  • Supported by documented equipment qualification.
  • Compliant with Good Manufacturing Practice expectations of the target market.

Why Semi-Solids and Liquids Require Distinct Scale-Up Approaches

Semi-solids and liquids behave differently under industrial conditions than they do in development laboratories. Viscosity, droplet size, phase stability and homogeneity are sensitive to vessel geometry, impeller design, temperature ramp rates and vacuum profiles.

For semi-solid manufacturing, the rheology of the product can shift markedly when emulsification is performed in a 1,000 litre vessel rather than a 5 litre laboratory mixer. For liquid production scaling, factors such as dissolution kinetics, aeration and sterilisation profiles must be reassessed at each step.

These dynamics mean that scale-up is rarely a simple multiplication of volumes. It is a deliberate engineering exercise built on data from pilot batches.

The Core Phases of Semi-Solid and Liquid Scale-Up

1. Technical Transfer and Process Characterisation

The first phase is the structured transfer of formulation knowledge from the originating site or laboratory to the commercial manufacturing site. This typically includes:

  • A gap analysis between development and commercial equipment.
  • Identification of critical process parameters and critical quality attributes.
  • Mapping of in-process controls to the analytical method portfolio.
  • Risk assessment using a structured tool such as Failure Mode and Effects Analysis.

At Adragos Pharma, technical transfer is treated as a defined project phase with cross-functional ownership across formulation development, manufacturing, quality assurance and regulatory affairs.

2. Equipment Fit and Engineering Assessment

Equipment fit is the determination of whether the receiving site’s vessels, homogenisers, filling lines and utilities can reproduce the developed process. For semi-solids this includes assessing:

  • Vessel geometry and impeller configuration.
  • Homogenisation tip speed and residence time.
  • Heating and cooling jacket performance.
  • Vacuum capability for de-aeration.

For liquids, the assessment focuses on mixing efficiency, filtration trains, filling accuracy and, where relevant, sterilisation cycles. When equipment is not a direct match, process parameters must be adapted and justified with supporting data.

3. Pilot and Engineering Batches

Pilot and engineering batches bridge the development scale and the commercial scale. They confirm that adjusted parameters deliver a product within specification and generate the data required for process validation. The output of this phase typically informs:

  • Final master batch records.
  • In-process control limits.
  • Cleaning validation strategy.
  • Stability programme design.

4. Process Validation and Commercial Drug Production

Process validation demonstrates, through three or more consecutive successful commercial batches, that the manufacturing process consistently produces material meeting predefined quality criteria. Once validation is complete, the product enters routine commercial drug production under continuous process verification, with deviations and trends monitored through the quality management system.

Common Scale-Up Challenges and How They Are Managed

ChallengeTypical CauseMitigation
Viscosity drift in semi-solidsDifferences in shear input between scalesAdjust homogenisation speed and duration based on pilot data
Phase separation in emulsionsInadequate cooling profile at larger scaleRedesign jacket cooling and add controlled holding steps
Content uniformity in suspensionsSettling during transfer or fillingOptimise in-line agitation and filling line residence time
Microbial control in aqueous liquidsExtended hold times in large vesselsDefine maximum hold periods supported by microbial challenge data
Regulatory variation riskChanges that exceed post-approval flexibilityPlan change strategy aligned to the relevant regulatory framework

These scale-up challenges are best addressed early in pharmaceutical process development, when formulation choices can still accommodate manufacturability considerations.

Quality Controls Across the Scale-Up Lifecycle

Quality oversight is continuous throughout scale-up. Typical control elements include analytical method transfer, in-process testing at defined hold points, finished product release testing and ongoing stability monitoring. The control strategy is documented and aligned with International Council for Harmonisation guidelines, including the principles of Quality by Design where applicable.

For semi-solid and liquid products, particular attention is given to:

  • Homogeneity and content uniformity.
  • Viscosity and rheological profile.
  • pH and osmolality where relevant.
  • Microbial quality and preservative efficacy.
  • Container closure integrity.

Regulatory Considerations for Scale-Up

Regulatory risk during scale-up is managed by ensuring that any changes between the developed process and the commercial process are documented, justified and, where required, reported to health authorities. The level of regulatory action depends on the product’s lifecycle stage and the markets involved. For products already approved, scale-up changes are typically managed through variation procedures aligned to the European Medicines Agency, the United States Food and Drug Administration or other applicable frameworks.

Working with a Contract Development and Manufacturing Organisation that has established regulatory infrastructure reduces the risk of unexpected filing requirements or inspection findings.

How Adragos Pharma Supports Semi-Solid and Liquid Scale-Up

Adragos Pharma provides integrated development, technical transfer and commercial manufacturing services for semi-solid and liquid pharmaceutical products. Its manufacturing network supports a range of batch sizes, with quality systems aligned to international Good Manufacturing Practice standards. Clients are supported through structured project management, formulation expertise and validated analytical capability across the scale-up lifecycle.

For pharma and biotech developers preparing for commercial launch, early engagement on equipment fit, process characterisation and regulatory strategy typically shortens the path from pilot to validated commercial supply.

Frequently Asked Questions

What is the main difference between semi-solid and liquid scale-up?

Semi-solid scale-up is dominated by rheology, shear and emulsion stability, whereas liquid scale-up focuses on mixing efficiency, dissolution, filtration and, for sterile products, sterilisation cycles. Both require equipment-specific characterisation rather than direct volumetric scaling.

When should scale-up planning begin?

Scale-up planning should begin during pharmaceutical process development, ideally before the formulation is locked. Early consideration of manufacturability reduces the likelihood of rework during pilot and validation phases.

How many batches are required for process validation?

Most regulatory frameworks expect a minimum of three consecutive successful commercial-scale batches, supported by a justified validation protocol and ongoing process verification.

Can scale-up be performed without changing the registered process?

Minor scale-up activities can often be accommodated within the existing registration, but significant changes to equipment, batch size or process parameters typically require a regulatory variation. The classification depends on the relevant authority and product type.

]]>
https://adragos-pharma.com/semi-solid-and-liquid-scale-up/feed/ 0